DEF 14C: Mustang Bio Stockholders Approve Warrant Share Issuance via Written Consent

Mustang Bio informs stockholders of the approval of a warrant share issuance by majority holders via written consent, aimed at complying with Nasdaq listing rules.

Summary

• Mustang Bio's majority stockholders approved the issuance of up to 34,767,934 common shares underlying certain outstanding warrants.
• This approval was obtained via written consent on January 10, 2025, in lieu of a stockholder meeting.
• The warrant share issuance relates to an investor inducement letter agreement and an engagement letter with H.C. Wainwright & Co., LLC.
• The company is providing this information statement to comply with SEC rules and Delaware law.
• A 1-for-50 reverse stock split was effected on January 15, 2025, but all share amounts in the information statement are pre-split.
• The warrant share issuance will become effective 20 days after the information statement is mailed to stockholders, expected around February 11, 2025.
• The majority holders held approximately 57% of the voting power necessary to approve the warrant share issuance.
• The company received approximately $4 million in gross proceeds from the exercise of existing warrants.
• H.C. Wainwright & Co., LLC received a cash fee equal to 7.0% of the aggregate gross proceeds from the exercise of the Existing Warrants.

Sentiment

Score: 5

Explanation: The announcement is neutral. While it secures funding, it also dilutes existing shareholders. The company is complying with Nasdaq rules, but the overall impact is mixed.

Positives

• The company received approximately $4 million in gross proceeds from the exercise of existing warrants, which will be used for working capital and general corporate purposes.
• The warrant share issuance allows the company to comply with Nasdaq listing rules.

Negatives

• The potential issuance of the warrant shares will result in substantial dilution of existing stockholders' percentage ownership.
• The company paid H.C. Wainwright & Co., LLC a cash fee equal to 7.0% of the aggregate gross proceeds from the exercise of the Existing Warrants.

Risks

• The potential issuance of the warrant shares would result in a substantial and significant increase in the number of shares of common stock outstanding.
• Current stockholders will incur substantial dilution of their percentage ownership if the warrant holders exercise their warrants.
• The company cannot predict whether or when the holders will exercise their warrants.

Future Outlook

The company intends to use the net proceeds from the warrant exercise for working capital and general corporate purposes and will use best efforts to keep the Resale Registration Statement effective at all times until the Investor no longer owns any New Warrants or New Warrant Shares.

Management Comments

• The Board determined to pursue stockholder action by written consent to eliminate costs and management time involved in obtaining proxies and to effect the above action as early as possible.

Industry Context

Many small cap biotech companies use warrant exercises and follow-on offerings to raise capital. This is a common practice, especially for companies that are pre-revenue or have limited revenue streams.

Comparison to Industry Standards

• Warrant exercises are a common funding mechanism for small-cap biotech companies like Mustang Bio.
• The 7% placement agent fee is within the typical range for such transactions, although it can vary based on the size and complexity of the deal.
• Comparable companies that have used similar financing methods include companies such as Cellectar Biosciences and Diffusion Pharmaceuticals.

Stakeholder Impact

• Existing stockholders will experience dilution of their ownership percentage.
• The company will have additional capital for working capital and general corporate purposes.

Next Steps

• The warrant share issuance will become effective 20 days after the information statement is mailed to stockholders.
• The company will continue to keep the Resale Registration Statement effective.

Key Dates

Keywords

warrant share issuance, Mustang Bio, stockholder approval, written consent, dilution, Nasdaq listing rule, reverse stock split, H.C. Wainwright, common stock, warrants